• G Cadiot, A Vuagnat, I Doukhan, A Murat, G Bonnaud, B Delemer, G Thiéfin, A Beckers, M Veyrac, C Proye, P Ruszniewski, and M Mignon.
• Service d'hépato-gastroentérologie, Centre Hospitalier Universitaire (CHU) Bichat Claude-Bernard, Paris, France.
• Gastroenterology. 1999 Feb 1; 116 (2): 286-93.

Background & AimsRisk factors of metachronous liver metastases and death are not well known in patients with the Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. These factors were retrospectively determined in 77 patients.MethodsData chart review was performed.ResultsMedian follow-up was 102 months (range, 12-366). Surgery was performed on 48 patients, including 9 of the 10 patients with large pancreatic tumors (>/=3 cm). Liver metastases developed in 4 patients (40%) with large pancreatic tumors, in 3 (4.8%) without, and in 1 of the 4 patients with pancreatic tumors of unknown size; all had previously undergone surgery. The only independent factor associated with development of liver metastases identified by multivariate analysis was large pancreatic tumors (risk ratio, 29.0; 95% confidence interval [CI], 3. 2-260.7). Surgery was not selected. The probability of being free of liver metastases in the 63 patients without large pancreatic tumors was 96% (95% CI, 88-100) at 10 and 15 years. Thirteen (16.9%) patients died. The only independent factors of death selected by multivariate analysis were Zollinger-Ellison syndrome diagnosis before 1980 (risk ratio, 8.2; 95% CI, 1.7-40.6) and age at diagnosis (risk ratio/year, 1.08; 95% CI, 1.03-1.14).ConclusionsLarge pancreatic tumors are predictive of the development of metachronous liver metastases, and surgery does not seem to prevent them.

25 keywords...

hide…